MF Researcher Database

Researchers Database

Advance

MUROYAMA RYOSUKE

Affiliation： Department of Microbiology
Position： Professor
Last Updated :2025/04/28

Profiles

Profiles

  • 氏名

    MUROYAMA RYOSUKE

Affiliation

  • Department of Microbiology, Professor

Research achievements

Published Papers

    Unclear
  • Vitamin K2 binds 17beta-hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism., Otsuka Motoyuki;Kato Naoya;Ichimura Tohru;Abe Shinya;Tanaka Yasuo;Taniguchi Hiroyoshi;Hoshida Yujin;Moriyama Masaru;Wang Yue;Shao Run-Xuan;Narayan Dharel;Muroyama Ryosuke;Kanai Fumihiko;Kawabe Takao;Isobe Toshiaki;Omata Masao, Life sciences, 76(21), 2473-2482, 08 Apr. 2005
    DOI
  • No mutations in the tyrosine kinases of human hepatic, pancreatic, and gastric cancer cell lines., Shao Run-Xuan;Otsuka Motoyuki;Kato Naoya;Chang Jin-Hai;Muroyama Ryosuke;Taniguchi Hiroyoshi;Moriyama Masaru;Wang Yue;Kawabe Tokao;Omata Masao, Journal of gastroenterology, 40(9), 918, Sep. 2005
    DOI
  • MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C., Dharel Narayan;Kato Naoya;Muroyama Ryosuke;Moriyama Masaru;Shao Run-Xuan;Kawabe Takao;Omata Masao, Clinical cancer research : an official journal of the American Association for Cancer Research, 12(16), 4867-4871, 15 Aug. 2006
    DOI
  • Absence of tyrosine kinase mutations in Japanese colorectal cancer patients., Shao R-X;Kato N;Lin L-J;Muroyama R;Moriyama M;Ikenoue T;Watabe H;Otsuka M;Guleng B;Ohta M;Tanaka Y;Kondo S;Dharel N;Chang J-H;Yoshida H;Kawabe T;Omata M, Oncogene, 26(14), 2133-2135, 02 Oct. 2006
    DOI
  • Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma., Muroyama Ryosuke;Kato Naoya;Yoshida Haruhiko;Otsuka Motoyuki;Moriyama Masaru;Wang Yue;Shao Run-Xuan;Dharel Narayan;Tanaka Yasuo;Ohta Miki;Tateishi Ryosuke;Shiina Shuichiro;Tatsukawa Masashi;Fukai Kenichi;Imazeki Fumio;Yokosuka Osamu;Shiratori Yasushi;Omata Masao, Journal of hepatology, 45(6), 805-812, 22 Sep. 2006
    DOI
  • Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus., Dharel Narayan;Kato Naoya;Muroyama Ryosuke;Taniguchi Hiroyoshi;Otsuka Motoyuki;Wang Yue;Jazag Amarsanaa;Shao Run-Xuan;Chang Jin-Hai;Adler Mark K;Kawabe Takao;Omata Masao, Hepatology (Baltimore, Md.), 47(4), 1136-1149, Apr. 2008
    DOI
  • Association of interferon regulatory factor-7 gene polymorphism with liver cirrhosis in chronic hepatitis C patients., Sermasathanasawadi Radsamee;Kato Naoya;Muroyama Ryosuke;Dharel Narayan;Shao Run-Xuan;Chang Jin-Hai;Li Chang-Zheng;Kawabe Takao;Omata Masao, Liver international : official journal of the International Association for the Study of the Liver, 28(6), 798-806, Jul. 2008
    DOI
  • Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma., Tada Motohisa;Kanai Fumihiko;Tanaka Yasuo;Tateishi Keisuke;Ohta Miki;Asaoka Yoshinari;Seto Motoko;Muroyama Ryosuke;Fukai Kenichi;Imazeki Fumio;Kawabe Takao;Yokosuka Osamu;Omata Masao, Clinical cancer research : an official journal of the American Association for Cancer Research, 14(12), 3768-3776, 15 Jun. 2008
    DOI
  • Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication., Li Chang-Zheng;Kato Naoya;Chang Jin-Hai;Muroyama Ryosuke;Shao Run-Xuan;Dharel Narayan;Sermsathanasawadi Radsamee;Kawabe Takao;Omata Masao, Liver international : official journal of the International Association for the Study of the Liver, 29(9), 1413-1421, 05 Jun. 2009
    DOI
  • Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment., Chang Jin-Hai;Kato Naoya;Muroyama Ryosuke;Taniguchi Hiroyoshi;Guleng Bayasi;Dharel Narayan;Shao Run-Xuan;Tateishi Keisuke;Jazag Amarsanaa;Kawabe Takao;Omata Masao, Liver international : official journal of the International Association for the Study of the Liver, 30(2), 311-318, 16 Oct. 2009
    DOI
  • Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma., Hu Zhongjie;Muroyama Ryosuke;Kowatari Norie;Chang Jinhai;Omata Masao;Kato Naoya, Cancer science, 100(12), 2465-2468, Dec. 2009
    DOI
  • Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma., Kumar Vinod;Kato Naoya;Urabe Yuji;Takahashi Atsushi;Muroyama Ryosuke;Hosono Naoya;Otsuka Motoyuki;Tateishi Ryosuke;Omata Masao;Nakagawa Hidewaki;Koike Kazuhiko;Kamatani Naoyuki;Kubo Michiaki;Nakamura Yusuke;Matsuda Koichi, Nature genetics, 43(5), 455-458, 17 Apr. 2011
    DOI
  • [New antivirals against hepatitis C virus(protease inhibitors, polymerase inhibitors, and host factor targeting antivirals)]., Kato Naoya;Muroyama Ryosuke, Nihon rinsho. Japanese journal of clinical medicine, 69 Suppl 4, 275-281, May 2011
  • [New antivirals against hepatitis C virus]., Kato Naoya;Muroyama Ryosuke;Goto Kaku, Nihon rinsho. Japanese journal of clinical medicine, 70(4), 664-670, Apr. 2012
  • Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma., Kumar Vinod;Yi Lo Paulisally Hau;Sawai Hiromi;Kato Naoya;Takahashi Atsushi;Deng Zhenzhong;Urabe Yuji;Mbarek Hamdi;Tokunaga Katsushi;Tanaka Yasuhito;Sugiyama Masaya;Mizokami Masashi;Muroyama Ryosuke;Tateishi Ryosuke;Omata Masao;Koike Kazuhiko;Tanikawa Chizu;Kamatani Naoyuki;Kubo Michiaki;Nakamura Yusuke;Matsuda Koichi, PloS one, 7(9), e44743, 14 Sep. 2012
    DOI
  • A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region., Urabe Yuji;Ochi Hidenori;Kato Naoya;Kumar Vinod;Takahashi Atsushi;Muroyama Ryosuke;Hosono Naoya;Otsuka Motoyuki;Tateishi Ryosuke;Lo Paulisally Hau Yi;Tanikawa Chizu;Omata Masao;Koike Kazuhiko;Miki Daiki;Abe Hiromi;Kamatani Naoyuki;Toyota Joji;Kumada Hiromitsu;Kubo Michiaki;Chayama Kazuaki;Nakamura Yusuke;Matsuda Koichi, Journal of hepatology, 58(5), 875-882, 12 Jan. 2013
    DOI
  • [Viral hepatitis]., Kato Naoya;Muroyama Ryosuke;Goto Kaku, Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 8, 583-588, Nov. 2012
  • IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection., Sato Masaya;Kato Naoya;Tateishi Ryosuke;Muroyama Ryosuke;Kowatari Norie;Li Wenwen;Goto Kaku;Otsuka Motoyuki;Shiina Shuichiro;Yoshida Haruhiko;Omata Masao;Koike Kazuhiko, Journal of gastroenterology, 49(4), 748-754, 22 May 2013
    DOI
  • Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection., Sato Masaya;Kato Naoya;Tateishi Ryosuke;Muroyama Ryosuke;Kowatari Norie;Li Wenwen;Goto Kaku;Otsuka Motoyuki;Shiina Shuichiro;Yoshida Haruhiko;Omata Masao;Koike Kazuhiko, Hepatology research : the official journal of the Japan Society of Hepatology, 44(10), E137-E144, 08 Jan. 2014
    DOI
  • Specific delivery of microRNA93 into HBV-replicating hepatocytes downregulates protein expression of liver cancer susceptible gene MICA., Ohno Motoko;Otsuka Motoyuki;Kishikawa Takahiro;Shibata Chikako;Yoshikawa Takeshi;Takata Akemi;Muroyama Ryosuke;Kowatari Norie;Sato Masaya;Kato Naoya;Kuroda Shun'ichi;Koike Kazuhiko, Oncotarget, 5(14), 5581-5590, 30 Jul. 2014
    DOI
  • The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels., Shibata Chikako;Ohno Motoko;Otsuka Motoyuki;Kishikawa Takahiro;Goto Kaku;Muroyama Ryosuke;Kato Naoya;Yoshikawa Takeshi;Takata Akemi;Koike Kazuhiko, Virology, 462-463, 42-48, 14 Jun. 2014
    DOI
  • [Hepatitis C virus induced hepatocellular carcinoma associated genes]., Kato Naoya;Muroyama Ryosuke;Goto Kaku, Nihon rinsho. Japanese journal of clinical medicine, 73(2), 333-338, Feb. 2015
  • The characteristic changes in hepatitis B virus x region for hepatocellular carcinoma: a comprehensive analysis based on global data., Li Wenwen;Goto Kaku;Matsubara Yasuo;Ito Sayaka;Muroyama Ryosuke;Li Qiang;Kato Naoya, PloS one, 10(5), e0125555, 05 May 2015
    DOI
  • [Development status of DAA against hepatitis C]., Kato Naoya;Nakagawa Ryo;Goto Kaku;Muroyama Ryosuke;Matsubara Yasuo, Nihon rinsho. Japanese journal of clinical medicine, 73 Suppl 9, 262-268, Dec. 2015
  • Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study., Goto Kaku;Annan Dorcas A;Morita Tomoko;Li Wenwen;Muroyama Ryosuke;Matsubara Yasuo;Ito Sayaka;Nakagawa Ryo;Tanoue Yasushi;Jinushi Masahisa;Kato Naoya, Scientific reports, 6, 38407, 02 Dec. 2016
    DOI
  • miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis., Nakagawa Ryo;Muroyama Ryosuke;Saeki Chisato;Goto Kaku;Kaise Yoshimi;Koike Kazuhiko;Nakano Masanori;Matsubara Yasuo;Takano Keiko;Ito Sayaka;Saruta Masayuki;Kato Naoya;Zeniya Mikio, Journal of hepatology, 66(6), 1223-1230, 10 Feb. 2017
    DOI
  • Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells., Arai Jun;Goto Kaku;Stephanou Anthony;Tanoue Yasushi;Ito Sayaka;Muroyama Ryosuke;Matsubara Yasuo;Nakagawa Ryo;Morimoto Sayuri;Kaise Yoshimi;Lim Lay Ahyoung;Yoshida Hitoshi;Kato Naoya, Journal of gastroenterology and hepatology, 33(5), 1075-1081, 06 Feb. 2018
    DOI
  • Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cells., Arai Jun;Goto Kaku;Tanoue Yasushi;Ito Sayaka;Muroyama Ryosuke;Matsubara Yasuo;Nakagawa Ryo;Kaise Yoshimi;Lim Lay Ahyoung;Yoshida Hitoshi;Kato Naoya, International journal of cancer, 143(10), 2575-2583, 22 Sep. 2018
    DOI
  • CD4+ T cells from patients with primary biliary cholangitis show T cell activation and differentially expressed T-cell receptor repertoires., Nakagawa Ryo;Muroyama Ryosuke;Saeki Chisato;Oikawa Tsunekazu;Kaise Yoshimi;Koike Kazuhiko;Arai Jun;Nakano Masanori;Matsubara Yasuo;Takano Keiko;Hirata Yoshihiro;Saruta Masayuki;Zeniya Mikio;Kato Naoya, Hepatology research : the official journal of the Japan Society of Hepatology, 49(6), 653-662, 26 Feb. 2019
    DOI
  • Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma., Maeda Takahiro;Kanzaki Hiroaki;Chiba Tetsuhiro;Ao Junjie;Kanayama Kengo;Maruta Susumu;Kusakabe Yuko;Saito Tomoko;Kobayashi Kazufumi;Kiyono Soichiro;Nakamura Masato;Ogasawara Sadahisa;Suzuki Eiichiro;Ooka Yoshihiko;Nakamoto Shingo;Nakagawa Ryo;Muroyama Ryosuke;Kanda Tatsuo;Maruyama Hitoshi;Kato Naoya, BMC cancer, 19(1), 1088, 12 Nov. 2019
    DOI
  • A Novel Role of Interleukin 13 Receptor alpha2 in Perineural Invasion and its Association with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma., Fujisawa Toshio;Shimamura Takeshi;Goto Kaku;Nakagawa Ryo;Muroyama Ryosuke;Ino Yoshinori;Horiuchi Hajime;Endo Itaru;Maeda Shin;Harihara Yasushi;Nakajima Atsushi;Matsuhashi Nobuyuki;Kato Naoya;Isayama Hiroyuki;Puri Ankit;Suzuki Akiko;Bellayr Ian;Leland Pamela;Joshi Bharat H;Puri Raj K, Cancers, 12(5), 20 May 2020
    DOI
  • Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding., Arai Jun;Goto Kaku;Otoyama Yumi;Nakajima Yoko;Sugiura Ikuya;Kajiwara Atsushi;Tojo Masayuki;Ichikawa Yuki;Uozumi Shojiro;Shimozuma Yuu;Uchikoshi Manabu;Sakaki Masashi;Nozawa Hisako;Nakagawa Ryo;Muroyama Ryosuke;Kato Naoya;Yoshida Hitoshi, Cancer immunology, immunotherapy : CII, 70(1), 203-213, 18 Jul. 2020
    DOI
  • Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer., Imai Yushi;Chiba Tetsuhiro;Kondo Takayuki;Kanzaki Hiroaki;Kanayama Kengo;Ao Junjie;Kojima Ryuta;Kusakabe Yuko;Nakamura Masato;Saito Tomoko;Nakagawa Ryo;Suzuki Eiichiro;Nakamoto Shingo;Muroyama Ryosuke;Tawada Akinobu;Matsumura Tomoaki;Nakagawa Tomoo;Kato Jun;Kotani Ai;Matsubara Hisahiro;Kato Naoya, Oncology letters, 20(3), 2161-2168, 19 Jun. 2020
    DOI
  • The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma., Kanzaki Hiroaki;Chiba Tetsuhiro;Ao Junjie;Koroki Keisuke;Kanayama Kengo;Maruta Susumu;Maeda Takahiro;Kusakabe Yuko;Kobayashi Kazufumi;Kanogawa Naoya;Kiyono Soichiro;Nakamura Masato;Kondo Takayuki;Saito Tomoko;Nakagawa Ryo;Ogasawara Sadahisa;Suzuki Eiichiro;Ooka Yoshihiko;Muroyama Ryosuke;Nakamoto Shingo;Yasui Shin;Tawada Akinobu;Arai Makoto;Kanda Tatsuo;Maruyama Hitoshi;Mimura Naoya;Kato Jun;Zen Yoh;Ohtsuka Masayuki;Iwama Atsushi;Kato Naoya, Scientific reports, 11(1), 5303, 05 Mar. 2021
    DOI
  • Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells., Ao Junjie;Chiba Tetsuhiro;Shibata Shuhei;Kurosugi Akane;Qiang Na;Ma Yaojia;Kan Motoyasu;Iwanaga Terunao;Sakuma Takafumi;Kanzaki Hiroaki;Kanayama Kengo;Kojima Ryuta;Kusakabe Yuko;Nakamura Masato;Saito Tomoko;Nakagawa Ryo;Kondo Takayuki;Ogasawara Sadahisa;Suzuki Eiichiro;Muroyama Ryosuke;Kato Jun;Mimura Naoya;Kanda Tatsuo;Maruyama Hitoshi;Kato Naoya, Biochemical and biophysical research communications, 549, 171-178, 03 Mar. 2021
    DOI
  • Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma., Ao Junjie;Chiba Tetsuhiro;Kanzaki Hiroaki;Kanayama Kengo;Shibata Shuhei;Kurosugi Akane;Iwanaga Terunao;Kan Motoyasu;Sakuma Takafumi;Qiang Na;Ma Yaojia;Kojima Ryuta;Kusakabe Yuko;Nakamura Masato;Kobayashi Kazufumi;Kiyono Soichiro;Kanogawa Naoya;Saito Tomoko;Nakagawa Ryo;Kondo Takayuki;Ogasawara Sadahisa;Suzuki Eiichiro;Nakamoto Shingo;Muroyama Ryosuke;Tawada Akinobu;Kato Jun;Kanda Tatsuo;Maruyama Hitoshi;Kato Naoya, Journal of Cancer, 12(9), 2694-2701, 05 Mar. 2021
    DOI
  • Retinoids Decrease Soluble MICA Concentration by Inhibiting the Enzymatic Activity of ADAM9 and ADAM10., Otoyama Yumi;Arai Jun;Goto Kaku;Nozawa Hisako;Nakagawa Ryo;Muroyama Ryosuke;Sugiura Ikuya;Nakajima Yoko;Kajiwara Atsushi;Tojo Masayuki;Ichikawa Yuki;Uozumi Shojiro;Shimozuma Yuu;Uchikoshi Manabu;Sakaki Masashi;Kato Naoya;Yoshida Hitoshi, Anticancer research, 41(5), 2307-2320, May 2021
    DOI
  • EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma., Kusakabe Yuko;Chiba Tetsuhiro;Oshima Motohiko;Koide Shuhei;Rizq Ola;Aoyama Kazumasa;Ao Junjie;Kaneko Tatsuya;Kanzaki Hiroaki;Kanayama Kengo;Maeda Takahiro;Saito Tomoko;Nakagawa Ryo;Kobayashi Kazufumi;Kiyono Soichiro;Nakamura Masato;Ogasawara Sadahisa;Suzuki Eiichiro;Nakamoto Shingo;Yasui Shin;Mikata Rintaro;Muroyama Ryosuke;Kanda Tatsuo;Maruyama Hitoshi;Kato Jun;Mimura Naoya;Ma Anqi;Jin Jian;Zen Yoh;Otsuka Masayuki;Kaneda Atsushi;Iwama Atsushi;Kato Naoya, Scientific reports, 11(1), 21396, 01 Nov. 2021
    DOI
  • Changes in therapeutic options for hepatocellular carcinoma in Asia., Ogasawara Sadahisa;Koroki Keisuke;Kanzaki Hiroaki;Kobayashi Kazufumi;Kiyono Soichiro;Nakamura Masato;Kanogawa Naoya;Saito Tomoko;Kondo Takayuki;Nakagawa Ryo;Nakamoto Shingo;Muroyama Ryosuke;Chiba Tetsuhiro;Kato Naoya, Liver international : official journal of the International Association for the Study of the Liver, 42(9), 2055-2066, 29 Nov. 2021
    DOI
  • Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment., Mukai Shohei;Kanzaki Hiroaki;Ogasawara Sadahisa;Ishino Takamasa;Ogawa Keita;Nakagawa Miyuki;Fujiwara Kisako;Unozawa Hidemi;Iwanaga Terunao;Sakuma Takafumi;Fujita Naoto;Koroki Keisuke;Kobayashi Kazufumi;Kanogawa Naoya;Kiyono Soichiro;Nakamura Masato;Kondo Takayuki;Saito Tomoko;Nakagawa Ryo;Suzuki Eiichiro;Ooka Yoshihiko;Muroyama Ryosuke;Nakamoto Shingo;Tawada Akinobu;Chiba Tetsuhiro;Arai Makoto;Kato Jun;Shiina Manayu;Ota Masayuki;Ikeda Jun-Ichiro;Takiguchi Yuichi;Ohtsuka Masayuki;Kato Naoya, JGH open : an open access journal of gastroenterology and hepatology, 5(11), 1266-1274, 01 Oct. 2021
    DOI
  • Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial., Ogasawara Sadahisa;Koroki Keisuke;Makishima Hirokazu;Wakatsuki Masaru;Takahashi Asahi;Yumita Sae;Nakagawa Miyuki;Ishino Takamasa;Ogawa Keita;Fujiwara Kisako;Iwanaga Terunao;Sakuma Takafumi;Fujita Naoto;Kojima Ryuta;Kanzaki Hiroaki;Kobayashi Kazufumi;Kiyono Soichiro;Nakamura Masato;Kanogawa Naoya;Saito Tomoko;Kondo Takayuki;Nakagawa Ryo;Nakamoto Shingo;Muroyama Ryosuke;Chiba Tetsuhiro;Ozawa Yoshihito;Kawasaki Yohei;Kurokawa Tomoya;Hanaoka Hideki;Tsuji Hiroshi;Kato Naoya, BMJ open, 12(4), e059779, 08 Apr. 2022
    DOI
  • Fusion HBx from HBV integrant affects hepatocarcinogenesis through deregulation of ER stress response., Muroyama Ryosuke;Nakagawa Ryo;Matsubara Yasuo;Hirata Yoshihiro;Omata Masao;Shirasawa Hiroshi;Kato Naoya, Virus research, 315, 198787, 14 Apr. 2022
    DOI
  • Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer., Arai Jun;Otoyama Yumi;Fujita Ken-Ichi;Goto Kaku;Tojo Masayuki;Katagiri Atsushi;Nozawa Hisako;Kubota Yutaro;Takahashi Takehiro;Ishida Hiroo;Tsunoda Takuya;Matsumoto Natsumi;Ogawa Keita;Nakagawa Ryo;Muroyama Ryosuke;Kato Naoya;Yoshida Hitoshi, BMC cancer, 22(1), 428, 20 Apr. 2022
    DOI
  • A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis., Sakuma Takafumi;Nakamura Masato;Chiba Tetsuhiro;Iwanaga Terunao;Kan Motoyasu;Kojima Ryuta;Ao Junjie;Ma Yaojia;Unozawa Hidemi;Fujita Naoto;Kanayama Kengo;Kanzaki Hiroaki;Koroki Keisuke;Kobayashi Kazufumi;Nakagawa Ryo;Kanogawa Naoya;Kiyono Soichiro;Kondo Takayuki;Saito Tomoko;Ogasawara Sadahisa;Nakamoto Shingo;Muroyama Ryosuke;Kato Jun;Kishimoto Takashi;Kato Naoya, Laboratory investigation; a journal of technical methods and pathology, 102(10), 1150-1157, 28 May 2022
    DOI
  • Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis., Ozeki Yusuke;Kanogawa Naoya;Ogasawara Sadahisa;Ogawa Keita;Ishino Takamasa;Nakagawa Miyuki;Fujiwara Kisako;Unozawa Hidemi;Iwanaga Terunao;Sakuma Takafumi;Fujita Naoto;Kojima Ryuta;Kanzaki Hiroaki;Koroki Keisuke;Kobayashi Kazufumi;Nakamura Masato;Kiyono Soichiro;Kondo Takayuki;Saito Tomoko;Nakagawa Ryo;Suzuki Eiichiro;Ooka Yoshihiko;Nakamoto Shingo;Muroyama Ryosuke;Tawada Akinobu;Chiba Tetsuhiro;Arai Makoto;Kato Jun;Ikeda Jun-Ichiro;Takiguchi Yuichi;Kato Naoya, International journal of clinical oncology, 27(9), 1459-1466, 15 Jun. 2022
    DOI
  • Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience., Ogawa Keita;Kanzaki Hiroaki;Chiba Tetsuhiro;Ao Junjie;Qiang Na;Ma Yaojia;Zhang Jiaqi;Yumita Sae;Ishino Takamasa;Unozawa Hidemi;Kan Motoyasu;Iwanaga Terunao;Nakagawa Miyuki;Fujiwara Kisako;Fujita Naoto;Sakuma Takafumi;Koroki Keisuke;Kusakabe Yuko;Kobayashi Kazufumi;Kanogawa Naoya;Kiyono Soichiro;Nakamura Masato;Kondo Takayuki;Saito Tomoko;Nakagawa Ryo;Ogasawara Sadahisa;Suzuki Eiichiro;Nakamoto Shingo;Muroyama Ryosuke;Kanda Tatsuo;Maruyama Hitoshi;Mimura Naoya;Kato Jun;Motohashi Shinichiro;Kato Naoya, Journal of Cancer, 13(8), 2656-2661, 16 May 2022
    DOI
  • The RNA-Binding Protein ELAVL1 Regulates Hepatitis B Virus Replication and Growth of Hepatocellular Carcinoma Cells., Kanzaki Hiroaki;Chiba Tetsuhiro;Kaneko Tatsuya;Ao Junjie;Kan Motoyasu;Muroyama Ryosuke;Nakamoto Shingo;Kanda Tatsuo;Maruyama Hitoshi;Kato Jun;Zen Yoh;Kotani Ai;Sekiba Kazuma;Otsuka Motoyuki;Ohtsuka Masayuki;Kato Naoya, International journal of molecular sciences, 23(14), 17 Jul. 2022
    DOI
  • Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus., Ma Yaojia;Nakamoto Shingo;Ao Junjie;Qiang Na;Kogure Tadayoshi;Ogawa Keita;Nakagawa Miyuki;Fujiwara Kisako;Iwanaga Terunao;Kojima Ryuta;Kanzaki Hiroaki;Koroki Keisuke;Kobayashi Kazufumi;Kanogawa Naoya;Kiyono Soichiro;Nakamura Masato;Kondo Takayuki;Nakagawa Ryo;Ogasawara Sadahisa;Muroyama Ryosuke;Chiba Tetsuhiro;Kato Jun;Kato Naoya, International journal of molecular sciences, 23(19), 10 Oct. 2022
    DOI
  • Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice., Nakagawa Miyuki;Inoue Masanori;Ogasawara Sadahisa;Maruta Susumu;Okubo Tomomi;Itokawa Norio;Iino Yotaro;Obu Masamichi;Haga Yuki;Seki Atsuyoshi;Kikuchi Yasuharu;Kogure Tadayoshi;Yumita Sae;Ishino Takamasa;Ogawa Keita;Fujiwara Kisako;Iwanaga Terunao;Fujita Naoto;Sakuma Takafumi;Kojima Ryuta;Kanzaki Hiroaki;Koroki Keisuke;Taida Takashi;Kobayashi Kazufumi;Kiyono Soichiro;Nakamura Masato;Kanogawa Naoya;Kondo Takayuki;Nakagawa Ryo;Nakamoto Shingo;Muroyama Ryosuke;Chiba Tetsuhiro;Itobayashi Ei;Atsukawa Masanori;Koma Yoshihiro;Azemoto Ryosaku;Ito Kenji;Mizumoto Hideaki;Shinozaki Masami;Kato Jun;Kato Naoya, Cancer, 129(4), 590-599, 24 Nov. 2022
    DOI
  • Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells., Iwanaga Terunao;Chiba Tetsuhiro;Nakamura Masato;Kaneko Tatsuya;Ao Junjie;Qiang Na;Ma Yaojia;Zhang Jiaqi;Kogure Tadayoshi;Yumita Sae;Ishino Takamasa;Ogawa Keita;Kan Motoyasu;Nakagawa Miyuki;Fujiwara Kisako;Fujita Naoto;Sakuma Takafumi;Kanzaki Hiroaki;Koroki Keisuke;Kusakabe Yuko;Inoue Masanori;Kobayashi Kazufumi;Kanogawa Naoya;Kiyono Soichiro;Kondo Takayuki;Nakagawa Ryo;Ogasawara Sadahisa;Nakamoto Shingo;Muroyama Ryosuke;Kato Jun;Kanda Tatsuo;Maruyama Hitoshi;Mimura Naoya;Honda Takuya;Murayama Toshihiko;Nakamura Hiroyuki;Kato Naoya, Biochemical and biophysical research communications, 642, 192-200, 10 Dec. 2022
    DOI
  • Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors., Ogawa Keita;Chiba Tetsuhiro;Nakamura Masato;Arai Jun;Zhang Jiaqi;Ma Yaojia;Qiang N A;Ao Junjie;Yumita Sae;Ishino Takamasa;Kan Motoyasu;Iwanaga Terunao;Nakagawa Miyuki;Fujiwara Kisako;Sakuma Takafumi;Kanzaki Hiroaki;Koroki Keisuke;Kusakabe Yuko;Kobayashi Kazufumi;Kanogawa Naoya;Kiyono Soichiro;Kondo Takayuki;Nakagawa Ryo;Ogasawara Sadahisa;Muroyama Ryosuke;Nakamoto Shingo;Kanda Tatsuo;Maruyama Hitoshi;Kato Jun;Matsumoto Shoji;Arai Takayoshi;Motohashi Shinichiro;Kato Naoya, Anticancer research, 43(3), 1043-1052, Mar. 2023
    DOI
  • Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma., Kanogawa Naoya;Ogasawara Sadahisa;Maruta Susumu;Iino Yotaro;Obu Masamichi;Ishino Takamasa;Ogawa Keita;Yumita Sae;Iwanaga Terunao;Unozawa Hidemi;Nakagawa Miyuki;Fujiwara Kisako;Sakuma Takafumi;Fujita Naoto;Kojima Ryuta;Kanzaki Hiroaki;Koroki Keisuke;Kobayashi Kazufumi;Inoue Masanori;Kiyono Soichiro;Nakamura Masato;Kondo Takayuki;Saito Tomoko;Nakagawa Ryo;Nakamoto Shingo;Muroyama Ryosuke;Chiba Tetsuhiro;Itobayashi Ei;Koma Yoshihiro;Azemoto Ryosaku;Kato Jun;Kato Naoya, BMC gastroenterology, 23(1), 70, 11 Mar. 2023
    DOI
  • Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma., Qiang Na;Ao Junjie;Nakamura Masato;Chiba Tetsuhiro;Kusakabe Yuko;Kaneko Tatsuya;Kurosugi Akane;Kogure Tadayoshi;Ma Yaojia;Zhang Jiaqi;Ogawa Keita;Kan Motoyasu;Iwanaga Terunao;Sakuma Takafumi;Kanayama Kengo;Kanzaki Hiroaki;Kojima Ryuta;Nakagawa Ryo;Kondo Takayuki;Nakamoto Shingo;Muroyama Ryosuke;Kato Jun;Mimura Naoya;Ma Anqi;Jin Jian;Kato Naoya, International immunopharmacology, 118, 110068, 29 Mar. 2023
    DOI
  • Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice., Yumita Sae;Ogasawara Sadahisa;Nakagawa Miyuki;Maruta Susumu;Okubo Tomomi;Itokawa Norio;Iino Yotaro;Obu Masamichi;Haga Yuki;Seki Atsuyoshi;Kogure Tadayoshi;Ishino Takamasa;Ogawa Keita;Fujiwara Kisako;Iwanaga Terunao;Fujita Naoto;Sakuma Takafumi;Kojima Ryuta;Kanzaki Hiroaki;Koroki Keisuke;Inoue Masanori;Kobayashi Kazufumi;Kiyono Soichiro;Nakamura Masato;Kanogawa Naoya;Saito Tomoko;Kondo Takayuki;Nakagawa Ryo;Nakamoto Shingo;Muroyama Ryosuke;Chiba Tetsuhiro;Itobayashi Ei;Atsukawa Masanori;Koma Yoshihiro;Azemoto Ryosaku;Ito Kenji;Mizumoto Hideaki;Kato Jun;Kato Naoya, BMC gastroenterology, 23(1), 101, 31 Mar. 2023
    DOI
  • PKR-NF-κB Pathway Upstream of IFN-β Induction Is Dysregulated in Oncolytic Sindbis Virus-infected HeLa Cells., Ma Xue;Ogawa Tomoko;Tian Zheng;Yi Ruirong;Tang Kang;Saito Kengo;Yatabe Sara;Ohno Yoshifumi;Muroyama Ryosuke;Ido Eiji;Matsubara Hisahiro;Shirasawa Hiroshi, Anticancer research, 43(7), 2923-2932, Jul. 2023
    DOI
  • Re-analysis of hepatitis B virus integration sites reveals potential new loci associated with oncogenesis in hepatocellular carcinoma., Kojima Ryuta;Nakamoto Shingo;Kogure Tadayoshi;Ma Yaojia;Ogawa Keita;Iwanaga Terunao;Qiang Na;Ao Junjie;Nakagawa Ryo;Muroyama Ryosuke;Nakamura Masato;Chiba Tetsuhiro;Kato Jun;Kato Naoya, World journal of virology, 12(3), 209-220, 25 Jun. 2023
    DOI
  • Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis., Kanzaki Hiroaki;Ogasawara Sadahisa;Okubo Tomomi;Itokawa Norio;Yoshino Ryohei;Fujimoto Kentaro;Kogure Tadayoshi;Yumita Sae;Ishino Takamasa;Ogawa Keita;Iwanaga Terunao;Nakagawa Miyuki;Fujiwara Kisako;Kojima Ryuta;Koroki Keisuke;Inoue Masanori;Kobayashi Kazufumi;Kanogawa Naoya;Kiyono Soichiro;Nakamura Masato;Kondo Takayuki;Nakagawa Ryo;Nakamoto Shingo;Muroyama Ryosuke;Itobayashi Ei;Atsukawa Masanori;Kato Jun;Kato Naoya, Drugs - real world outcomes, 10(4), 513-520, 19 Jul. 2023
    DOI

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.